Alcon Debt to Equity Ratio 2019-2022 | ALC

Current and historical debt to equity ratio values for Alcon (ALC) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Alcon debt/equity for the three months ending September 30, 2022 was 0.20.
Alcon Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-09-30 $8.15B $19.65B 0.42
2022-06-30 $8.19B $19.54B 0.42
2022-03-31 $8.30B $19.49B 0.43
2021-12-31 $8.74B $19.26B 0.45
2021-09-30 $8.71B $19.09B 0.46
2021-06-30 $8.69B $19.06B 0.46
2021-03-31 $8.46B $18.91B 0.45
2020-12-31 $8.78B $18.82B 0.47
2020-09-30 $8.76B $18.66B 0.47
2020-06-30 $8.71B $18.77B 0.46
2020-03-31 $8.03B $19.17B 0.42
2019-12-31 $8.35B $19.30B 0.43
2019-09-30 $8.25B $19.39B 0.43
2019-06-30 $8.32B $19.45B 0.43
2019-03-31 $0.00B $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B $0.00B 0.00
2018-06-30 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $34.365B $8.291B
Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $220.806B 23.09
Edwards Lifesciences (EW) United States $47.328B 32.57
STERIS (STE) Ireland $19.157B 23.84
Teleflex (TFX) United States $11.378B 18.46
Fresenius Medical Care AG KGaA (FMS) Germany $9.600B 9.64
Penumbra (PEN) United States $8.008B 1916.82
Globus Medical (GMED) United States $7.483B 38.05
Integer Holdings (ITGR) United States $2.426B 19.47
Glaukos (GKOS) United States $2.281B 0.00
Nevro (NVRO) United States $1.601B 0.00
Paragon 28 (FNA) United States $1.511B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.261B 17.96
Artivion (AORT) United States $0.546B 0.00